---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-002757"
form_type: "8-K"
ticker: "SRRK"
cik: "0001727196"
company_name: "Scholar Rock Holding Corp"
filed_at: "2026-01-12T23:59:59+00:00"
generated_at: "2026-05-16T10:54:18.985879+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Scholar Rock provides 2026 priorities; ~$365M cash; apitegromab BLA resubmission expected in 2026

## Summary
- Preliminary cash of ~$365M as of Dec 31, 2025; expected runway into 2027.
- Apitegromab BLA resubmission for SMA anticipated in 2026; U.S. launch expected after FDA approval.
- IND cleared for FSHD; Phase 2 FORGE trial initiation and dosing expected mid-2026.
- Subcutaneous apitegromab Phase 1 completed; SRK-439 Phase 1 topline data expected H2 2026.
- EMA MAA decision for apitegromab expected mid-2026; second U.S. fill-finish facility capacity reserved.

## SEC filing metadata
- accession: 0001104659-26-002757
- form_type: 8-K
- ticker: SRRK
- cik: 0001727196
- company_name: Scholar Rock Holding Corp
- filed_at: 2026-01-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1727196/000110465926002757/0001104659-26-002757-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1727196/000110465926002757/srrk-20260112x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-002757
- JSON: https://secwatch.observer/filing/0001104659-26-002757.json
- Plain text: https://secwatch.observer/filing/0001104659-26-002757.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.